Prognostic value of mesothelin expression in patients with triple negative and HER2-positive breast cancers - 14/03/15
, Ahmet Alacacioglu a, Murat Akyol a, Lutfiye Demir a, Ahmet Dirican a, Yasar Yildiz a, Tarik Salman a, Mustafa Oktay Tarhan aBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 6 |
| Iconographies | 4 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
Purpose |
Mesothelin is a cell surface glycoprotein that is overexpressed in various malignancies. Recent studies have revealed that mesothelin plays an oncogenic role in tumor growth and drug resistance through the Wnt/NF-κB/PI3K/Akt signaling pathways. Herein, the expression of mesothelin in HER2-positive and triple-negative breast cancer (TNBC) has been correlated with prognosis.
Methods |
A total of 430 patients with breast cancer treated between 2006 and 2013 were retrospectively reviewed; of these, 123 cases were considered TNBC (n=71; 58%) or were positive for HER2 (n=52; 42%). Mesothelin expression was assessed by immunohistochemistry.
Results |
Of the patients with TNBC, 30 (42.3%) were positive for mesothelin expression, compared to only two (3.8%) of the HER2-positive cases. As most HER2-positive tumors were negative for mesothelin staining, statistical analysis was not performed. Median overall survival (OS) was 70.1months for patients with TNBC, whereas median OS was 70.1months, in the mesothelin-positive group and 74.5months in mesothelin-negative group, respectively. Strong correlation was seen between mesothelin expression and tumor grade in patients with TNBC (P<0.005). In a multivariable Cox proportional hazards model, mesothelin expression was not independently associated with OS in patients with TNBC.
Conclusions |
Expression of mesothelin was observed in 42.3% of patients with TNBC and demonstrated a strong association with tumor grade. However, its expression was not correlated with prognosis.
Le texte complet de cet article est disponible en PDF.Keywords : Mesothelin, Cell surface proteins, Breast cancer, Her-2/Neu positive, Triple negative, Cell survival/proliferation
Plan
Vol 70
P. 190-195 - mars 2015 Retour au numéro
Article précédent
- The cancer pain related factors affected by celecoxib together with cetuximab in head and neck squamous cell carcinoma
- Yaqiong Yang, Jia Yan, Yan Huang, Hui Xu, Ying Zhang, Rong Hu, Jue Jiang, Zhifeng Chen, Hong Jiang
- Targeted concurrent chemoradiotherapy, by using improved microcapsules that release carboplatin in response to radiation, improves detectability by computed tomography as well as antitumor activity while reducing adverse effect in vivo
- Satoshi Harada, Shigeru Ehara, Keizo Ishii, Takahiro Sato, Masashi Koka, Tomihiro Kamiya, Koichiro Sera, Shyoko Goto
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?